Download Free Medical HPV and Oropharyngeal Cancer PowerPoint Presentation

HPV and Oropharyngeal Cancer PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation on cancer titled "HPV & Oropharyngeal Cancer" describes the differences in epidemiology and clinical presentation between HPV+ and HPV- oropharyngeal cancers, presents potential impact of HPV vaccination of the incidence of oropharyngeal cancer, and discusses the emerging strategies for prevention and early detection of oropharyngeal cancer.

Tags : Cancer, HPV, Oropharyngeal Cancer, epidemiology, clinical presentation, HPV+, HPV-, impact, vaccination, prevention, detection, Risk factors, tobacco, alcohol, HPV infection, oral, signs or symptoms

Published on : May 03, 2021 | Views : 2050 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

HPV & Oropharyngeal Cancer Mahnaz Fatahzadeh, DMD MSD Professor, Division of Oral Medicine fatahza@sdm.rutgers.edu
Slide 2-

Objectives To describe differences in epidemiology and clinical presentation between HPV+ and HPV- oropharyngeal cancers To describe potential impact of HPV vaccination of the incidence of oropharyngeal cancer To discuss the emerging strategies for prevention and early detection of oropharyngeal cancer
Slide 3-

JADA 2011;142(8):915-924
Slide 4-

Oropharyngeal cancer (OPC) Risk factors Traditional- tobacco & alcohol Emerging- HPV infection Alarming rise in oropharyngeal ca in middle aged (40-50) males without traditional risk factors 70% of oropharyngeal cancers in the US are HPV-related squamous cell carcinomas An epidemic of HPV-mediated malignancy projected to surpass the incidence rate of cervical cancer by 2020 in US The New Face of Head and Neck Cancer: The HPV Epidemic Oncology Sep2015
Slide 5-

HPV infection Small DNA viruses with predilection for mucocut-aneous keratinocytes in humans, > 100 subtypes Most common sexually transmitted infection > than 50% of sexually active will have genital infection at some time during their lives A Small percent will have oral infection at any given time of which only 1% are oncogenic subtypes The New Face of Head and Neck Cancer: The HPV Epidemic Oncology Sep2015
Slide 6-

Oral HPV infection No associated signs or symptoms No treatment for active oral HPV infection Majority clear the virus within 2 years Smoking increases the risk of oral HPV infection In some people infection may persist & progress to OPC HPV+ tumors are biologically and clinically distinct cancers The New Face of Head and Neck Cancer: The HPV Epidemic Oncology Sep2015
Slide 7-

The New Face of Head and Neck Cancer: The HPV Epidemic Oncology Sep2015
Slide 8-

HPV+ Oropharyngeal Ca Palatine & lingual tonsils are uniquely susceptible to HPV infection (immune-privileged sites) Primary tumors are often small and hidden in depth of tonsillar crypts Lack of signs & symptoms in early OPC Most frequent presentation is asymptomatic metastatic cervical swelling The New Face of Head and Neck Cancer: The HPV Epidemic Oncology Sep2015
Slide 9-

HPV+ Oropharyngeal Ca Prognosis & Prevention Better prognosis with current therapies than tobacco-related OPC (treatment implications!) Difficult to inspect oropharynx for precancerous lesions without specialized instruments Tonsillar crypts are inaccessible for sampling No validated screening test available The New Face of Head and Neck Cancer: The HPV Epidemic Oncology Sep2015
Slide 10-

Majority of virally-mediated OPC are caused by HPV16 (main subtype involved in cervical cancer).(1) Our knowledge about the natural history (incidence & clearance) of oral HPV infection is limited.(1) Need prospective studies to examine temporal relationship between oral HPV detection and risk of OPC.(1) Recent study analyzed 132 HNSCC and 396 controls nested within 2 prospective cohorts & found presence of HPV-16 in the oral cavity precedes the development of oropharyngeal cancers. Individuals with oral HPV-16 infection were 22 times more likely to develop oropharyngeal cancer compared with those without HPV infection.(2) Oral HPV Infection Natural history Takes R, et al. HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs. Oral Oncology 2015; 51: 1057–60. Agalliu I, et al. Associations of Oral α-, β-, and γ-Human Papillomavirus Types With Risk of Incident Head and Neck CancerJAMA Oncol. Jan 2016
Slide 11-

Oral HPV Infection Role of immune response Risk of oral HPV infection or cancer in mouth or throat from oral sex is lower in women with a greater # of vaginal sex partners Men are twice likely to suffer from cancer related to HPV from oral sex compared to women (ie. risk of HPV infection & cancer increases with the number of oral sex partners) HPV exposure via vaginal sex elicits an immune response protective against oral HPV infection and subsequent cancer Men are less likely to clear oral HPV infection (less effective immune response) Oral retention of HPV promotes cellular alterations which may result in oral malignancy Presentation at annual meeting of AAAS by Gypsyamber D'Souza from Johns Hopkins University Feb 2016
Slide 12-

Currently approved HPV vaccines protect against oncogenic HPV implicated in cervical and anal cancer as well as strains causing anogenital warts. (1) Although not evaluated in RCT, HPV vaccination may also prevent oral HPV infection & HPV-induced oropharyngeal malignancy. (1) 2014 CDC study suggests currently available HPV vaccines could prevent most oropharyngeal cancers in the U.S. (2) Costa Rica Vaccine Trial (CVT) shows vaccine efficacy against HPV16 and HPV18 (HPV16/18) infections at the cervical, anal, and oral regions among naive women. (3) 1) Takes R, et al. HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs. Oral Oncology 2015; 51: 1057 2) Steinau M, et al. Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States Emerging Infectious Diseases, 2014; 20:5, pp. 822-828 3) Beachler D, et al. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.J Natl Can Ins. Oct 2015 HPV vaccination Impact on OPC
Slide 13-

Source: MMWR July 31, 2015 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
Slide 14-

Vaccine Financing Private insurance Public financing Vaccines for Children (VFC) Program Federal funding for Medicaid-eligible, uninsured, American Indian or Alaska Native, or underinsured Immunization Grant Program Through a federal grant, CDC awards federal grants to state, local, and territorial public health agencies to aid with vaccine costs. Medicaid State Children’s Health Insurance Program (CHIP) Merck and GlaxoSmithKline assistance program for uninsured low income adults HPV Vaccine: Access and Use in the U.S The Henry Kaiser Family Foundation The Sep 2015
Slide 15-

HPV Vaccine: Access and Use in the U.S The Henry Kaiser Family Foundation The Sep 2015
Slide 16-

Emerging Best Practices Communication Raising public awareness about signs, symptoms, risk factors & change in demographic of oral cancer Evaluating risk profile of patients through a questionnaire and direct conversation Assessing readiness to quit smoking/alcohol & refer as indicated Inquiring parents about HPV vaccination of their children Asking patients about voice changes (hoarseness), lump in throat/neck, swallowing difficulty Repeating patient education at every visit
Slide 17-

Emerging Best Practices Examination Screening every patient starting at age 15 Performing regular & thorough inspection of head, neck & oral tissues Informing patients when you are screening for oral cancer Documenting all signs/symptoms Having a low threshold for referral if signs or symptoms persist Instructing patients how to perform self exam between visits
Slide 18-

References Lewis A, Kang R, Levine A, Maghami E. The New Face of Head and Neck Cancer: The HPV Epidemic. Oncology J, Head & Neck Ca Sep 2015 Agalliu I, Gapstur S, Chen Z, Wan T, Andersen R, Teras L, et al. Associations of Oral α-, β-, and γ-Human Papillomavirus Types With Risk of Incident Head and Neck Cancer. JAMA Oncol. Jan 2016 Beachler D, Kreimer A, Schiffman M, Herrero R, Wacholder S. Rodriguez A. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. J Natl Can Ins. Oct 2015 Steinau M, et al. Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States Emerging Infectious Diseases, 2014;20:5, pp. 822-8. Takes R, et al. HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs. Oral Oncology 2015; 51: 1057–60. The HPV Vaccine: Access and Use in the US. The Henry Kaiser Family Foundation Fact sheet. September 2015.
Slide 19-

Thank you fatahza@sdm.rutgers.edu